Xcelerate (XCRT) Stock News

Xcelerate (OTCQB:XCRT) has filed two utility patent applications (18/187,352 and 18/189,441) along with corresponding PCT applications (PCT/US2023/015755 and PCT/US2023/016194), building on its prior application from March 24, 2022. The patents focus on surgical tools with targeting guidance and reflect the company's mission to integrate engineering advancements into clinical care. CEO Michael O'Shea highlighted the importance of parallel development and intellectual property protection in their surgical device lines. The company is advancing its In-Tool-Optics prototypes that enhance surgical precision by offering a first-person view. Three product lines are being developed: ITO-Responder for emergency use, ITO-Clinic for hospital environments, and ITO-Infirmary for retrofitting existing tools. This initiative aims to improve efficiency in surgical procedures.

Xcelerate (OTCQB:XCRT) has concluded due diligence and entered into a binding agreement to acquire a controlling interest in ESN Group, Inc. The total transaction value is approximately $350,000 in cash, alongside the issuance of restricted stock, assumption of debt, and employment agreements for essential personnel. The acquisition is anticipated to close by June 30, 2023. This strategic purchase is positioned to provide Xcelerate with an immediate revenue stream and strengthen its portfolio in healthcare and skincare products. CEO Mike O'Shea indicated plans to expand product offerings into mass merchant outlets and government agencies, leveraging ESN's management expertise and industry connections.

Xcelerate, Inc. (OTCQB:XCRT) has signed an agreement with Afya Sasa Africa to implement AI-based healthcare services at Muhimbili National Hospital in Tanzania, the largest hospital in East Africa. This initiative aims to enhance healthcare delivery for Tanzania's 64 million people through advanced technology. The agreement includes multiple revenue streams such as member fees and consultation fees, with anticipated revenue starting in Q4 2023. The project phases include IT assessments and launching a cardiac module, with plans for nationwide expansion pending successful implementation.

Xcelerate, Inc. (OTCQB:XCRT) has announced the appointment of Fabian Urquijo to its Xcelerate Brands Advisory Board. Urquijo, an experienced marketing professional, brings 21 years of expertise from Procter & Gamble and Revlon, where he held senior marketing roles. His background includes managing various product categories, helping shape brand strategy, and driving innovation. CEO Michael O'Shea noted that Urquijo's experience is expected to support the development of a new portfolio of clean skin and personal care products. Furthermore, Urquijo will play a key role as Xcelerate moves forward with due diligence for acquiring a controlling interest in The ESN Group.

Xcelerate, Inc. (OTCQB:XCRT) has executed a letter of intent to acquire a controlling interest in ESN Group, Inc., which specializes in health care and skin care products. This acquisition is currently in a 60-day due diligence phase, aiming to finalize transaction agreements. ESN operates two revenue-generating brands: Ceramedx, known for its facial cleansers utilizing exclusive natural ceramide technology, and Earth Science Beauty, offering plant-based personal care solutions. If successful, the deal is projected to contribute millions in first-year revenue to Xcelerate. The company is also forming a division to expand its healthcare product lines.

Xcelerate, Inc. (OTCQB:XCRT) CEO Mike O'Shea provided a shareholder update on January 3, 2023, reflecting on a busy 2022. Key achievements include:

• Qualified a Regulation A offering with the SEC.
• Acquired AfiyaSasa Africa LLC and a patent portfolio from HS Pharmaceuticals.
• Patented a surgical tool enhancing precision.
• Uplisted to OTCQB and removed 'shell company' status.

In 2023, Xcelerate aims to generate revenue through a new subsidiary, Xcelerate Brands, and launch the AfiyaSasa program in Q2.

Xcelerate, Inc. (OTCQB:XCRT) announced its initiative to develop over-the-counter healthcare products utilizing its patent portfolio acquired from HS Pharmaceutical. Following productive meetings with HS Pharmaceuticals’ staff, the company aims to identify marketing and manufacturing partners to bring these products to market. The acquisition represents significant investment and research. CEO Michael O'Shea highlighted the potential for generating revenue in the near term through this initiative.

Xcelerate (OTCQB:XCRT) announced the granting of patent protection in nine additional countries, enhancing its intellectual property portfolio. This includes a Korean patent for a nanosilica composition aimed at stimulating T lymphocytes to treat conditions like cancer and inflammatory diseases. Further, a Eurasian patent has been approved covering several countries, including Russia and Kazakhstan. Xcelerate's CEO, Michael O'Shea, emphasized ongoing collaborative efforts with U.S. research institutions to advance its R&D initiatives.

Xcelerate, Inc. (OTCQB:XCRT) has received approval from the OTC Market Group to uplist to the OTCQB Venture Market. Trading will commence on August 1, 2022. CEO Michael O'Shea emphasized that this move aims to enhance transparency and liquidity for shareholders, while expanding the company’s reach to potential investors. The OTCQB is recognized by the SEC and serves as a public market for early-stage companies, requiring compliance with stringent disclosure and financial standards. Xcelerate operates in the medical industry, focusing on medical equipment rights and virtual health technology development.